Intuitive Surgical (NASDAQ:ISRG) Cut to Hold at Zacks Research

Zacks Research lowered shares of Intuitive Surgical (NASDAQ:ISRG) from a strong-buy rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports.

A number of other brokerages have also recently weighed in on ISRG. Daiwa Capital Markets lifted their price objective on shares of Intuitive Surgical from $510.00 to $550.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. UBS Group reissued a “neutral” rating on shares of Intuitive Surgical in a research note on Thursday, January 15th. Jefferies Financial Group boosted their price target on shares of Intuitive Surgical from $550.00 to $560.00 and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. Finally, Rothschild & Co Redburn raised their price objective on shares of Intuitive Surgical from $610.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $617.57.

Intuitive Surgical Trading Down 0.3%

Shares of NASDAQ ISRG opened at $523.99 on Wednesday. Intuitive Surgical has a 12-month low of $425.00 and a 12-month high of $609.08. The company has a market cap of $187.84 billion, a PE ratio of 66.41, a P/E/G ratio of 4.28 and a beta of 1.67. The stock has a 50 day simple moving average of $562.32 and a 200-day simple moving average of $511.79.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.18% and a net margin of 28.38%.The firm had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the business earned $2.21 EPS. The firm’s revenue for the quarter was up 18.8% on a year-over-year basis. Sell-side analysts forecast that Intuitive Surgical will post 6.43 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other news, SVP Mark Brosius sold 464 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $548.49, for a total transaction of $254,499.36. Following the sale, the senior vice president directly owned 131 shares of the company’s stock, valued at $71,852.19. The trade was a 77.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Craig H. Barratt sold 750 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $580.00, for a total value of $435,000.00. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 55,714 shares of company stock worth $31,617,799. 0.70% of the stock is owned by corporate insiders.

Institutional Trading of Intuitive Surgical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC raised its holdings in shares of Intuitive Surgical by 24.9% during the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after acquiring an additional 731 shares during the period. Sivia Capital Partners LLC grew its position in Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock worth $504,000 after purchasing an additional 34 shares in the last quarter. McAdam LLC grew its position in Intuitive Surgical by 10.1% during the 2nd quarter. McAdam LLC now owns 738 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 68 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of Intuitive Surgical by 4.0% in the second quarter. Perigon Wealth Management LLC now owns 9,419 shares of the medical equipment provider’s stock valued at $5,118,000 after purchasing an additional 366 shares in the last quarter. Finally, Fortune Financial Advisors LLC lifted its holdings in shares of Intuitive Surgical by 18.4% in the second quarter. Fortune Financial Advisors LLC now owns 856 shares of the medical equipment provider’s stock valued at $465,000 after purchasing an additional 133 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Q4 results beat Wall Street: Revenue and adjusted EPS topped estimates, backed by higher procedure volumes and system demand — a primary near‑term driver of recurring instrument sales. Reuters: Intuitive Surgical beats quarterly estimates on demand for surgical robots
• Positive Sentiment: Analysts boost some targets and reaffirm conviction: Bernstein raised its target sharply (big upside), Raymond James and BTIG reaffirmed/outperform with higher targets — supporting upside potential from elongation of the company’s growth runway. Benzinga: Analysts revise forecasts after Q4
• Neutral Sentiment: Guidance is measured: Management expects mid‑teens da Vinci procedure growth (midpoint ~14%) and 2026 gross margin around 67–68%, while flagging higher operating expenses for R&D — signaling steady growth but potential margin/operating‑leverage moderation. MarketBeat: Intuitive Surgical Just Proved the Growth Engine Still Runs
• Neutral Sentiment: JURA clinical update and milestone PRs add long‑term optionality: Early imaging data from the JURA feasibility study and a new 20 million‑patient da Vinci milestone reinforce long‑term growth narratives beyond core platforms. TipRanks: JURA feasibility study update GlobeNewswire: 20 Million Patients Benefit from da Vinci Surgery
• Negative Sentiment: Tariffs and gross‑margin pressure noted: Management expects tariffs to cut gross margins (about a 1.2% headwind in 2026) and flagged some gross‑margin decline vs. recent quarters — a medium‑term profitability risk. Zacks: Q4 beat but gross margin declines
• Negative Sentiment: Mixed analyst moves and a few downgrades: Some firms trimmed targets or moved to in‑line/hold (Evercore, Zacks), creating near‑term debate over valuation vs. growth and muting upside for traders focused on short‑term catalysts. The Fly: Evercore lowers price target

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.